Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TS-1 in Combination with ABI-007 in Unresectable or Recurrent Gastric Cancer
jRCT2080221526Phase 1
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegafur and nab-paclitaxel in gastric adenocarcinoma and gastric cancer (GC), sponsored by Taiho Pharmaceutical Co., Ltd.
02
Drugs
tegafurnab-paclitaxel
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080221526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221526.